Introduction: The glioblastoma is a malignant tumor, responsible for about 50% of primary tumor of central nervous system (CNS). However, not much is studied in infiltrative portion of glioblastomas about immunohistochemical characteristics when compared to the solid portion. Specially if this could mean that the infiltrative portion is less aggressive than solid portion. As this two portions have different characterisics at macroscopy and in image studies as well, we could imagine that they have different behavior in immunohistochemical studies. And, as largely accepted nowadays, the gross total ressection (ressection of solid portion) has an important role in a longer survival, so we can assume that the solid portion is immunohistochemically more aggressive than infiltrative portion.

Methods: We made a retrospective study with data collected from 10 consecutive adult patients (18 years old or more), from both genders, with confirmed diagnostic of glioblastoma. With surgeries performed at Hospital São Paulo, by Neurosurgery discipline of Escola Paulista de Medicina/UNIFESP. All of them with pre operative MRI and post operative MRI (within 48 h from surgery) showing gross total ressection of the lesion (total ressection of solid portion of glioblastoma), between january 2009 and december 2012.

Results: When compared the final anatomopathologic result with samples only from solid portion there was no difference. When we compared the anatomopathological findings between solid and infiltrative portions there was difference. The GFAP expression is the same in samples from both portions which characterize glial neoplasms. But the expression of p53, CD34, VEGF and Ki67 was more intense at solid portion than at infiltrative portion.

Conclusions: We showed that the difference seen at macroscopy and image studies are also reflected on the expression of cellular and vascular immunohistochemical markers. And more, that expression is more intense in solid portion than the infiltrative portion.

Patient Care: Pointing targets for future treatments in glioblastoma to increase overall survival and specially disease free survival.

Learning Objectives: Show the increasing role of immunohistochemistry in glioblastoma different portions, as a potential targets for future treatments.

References: 1- Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., & Wrensch, M. (2006). Epidemiology and molecular pathology of glioma. Nature Clinical Practice Neurology, 2(9), 494–503. doi:10.1038/ncpneuro0289 2- Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014). Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 23(10), 1985–1996. doi:10.1158/1055-9965.EPI-14-0275 3- Posti, J. P., Bori, M., Kauko, T., Sankinen, M., Nordberg, J., Rahi, M., et al. (2014). Presenting symptoms of glioma in adults. Acta Neurologica Scandinavica. doi:10.1111/ane.12285 4- Molenaar, R. J., Verbaan, D., Lamba, S., Zanon, C., Jeuken, J. W. M., Boots-Sprenger, S. H. E., et al. (2014). The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro-Oncology, 16(9), 1263–1273. doi:10.1093/neuonc/nou005 5- Jain, R., Poisson, L. M., Gutman, D., Scarpace, L., Hwang, S. N., Holder, C. A., et al. (2014). Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology, 272(2), 484–493. doi:10.1148/radiol.14131691 6- Rygh, O. M., Selbekk, T., Torp, S. H., Lydersen, S., Hernes, T. A. N., & Unsgaard, G. (2008). Comparison of navigated 3D ultrasound findings with histopathology in subsequent phases of glioblastoma resection. Acta Neurochirurgica, 150(10), 1033–41– discussion 1042. doi:10.1007/s00701-008-0017-3 7- Chacko, A. G., Kumar, N. K. S., Chacko, G., Athyal, R., & Rajshekhar, V. (2003). Intraoperative ultrasound in determining the extent of resection of parenchymal brain tumours--a comparative study with computed tomography and histopathology. Acta Neurochirurgica, 145(9), 743–8– discussion 748. doi:10.1007/s00701-003-0009-2 8- Croteau, D., Scarpace, L., Hearshen, D., Gutierrez, J., Fisher, J. L., Rock, J. P., & Mikkelsen, T. (2001). Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery, 49(4), 823–829. 9- Moliterno, J. A., Patel, T. R., & Piepmeier, J. M. (2012). Neurosurgical approach. Cancer Journal (Sudbury, Mass.), 18(1), 20–25. doi:10.1097/PPO.0b013e3183243f6e3 10- Kowalczuk, A., Macdonald, R. L., Amidei, C., Dohrmann, G., Erickson, R. K., Hekmatpanah, J., et al. (1997). Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery, 41(5), 1028–36– discussion 1036–8. 11- Yamahara, T., Numa, Y., Oishi, T., Kawaguchi, T., Seno, T., Asai, A., & Kawamoto, K. (2010). Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. Brain Tumor Pathology, 27(2), 81–87. doi:10.1007/s10014-010-0275-7 12- Silbergeld, D. L., & Chicoine, M. R. (1997). Isolation and characterization of human malignant glioma cells from histologically normal brain. Journal of Neurosurgery, 86(3), 525–531. doi:10.3171/jns.1997.86.3.0525 13- Yuile, P., Dent, O., Cook, R., Biggs, M., & Little, N. (2006). Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables. Journal of Clinical Neuroscience, 13(7), 747–751. http://doi.org/10.1016/j.jocn.2005.10.011 14- Preusser, M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., & Stupp, R. (2011). Current concepts and management of glioblastoma. Annals of Neurology, 70(1), 9–21. http://doi.org/10.1002/ana.22425 15- Song, W., Ruder, A. M., Hu, L., Li, Y., Ni, R., Shao, W., et al. (2009). Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs. PloS One, 4(9), e7157. http://doi.org/10.1371/journal.pone.0007157 16- Darefsky, A. S., King, J. T., & Dubrow, R. (2012). Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer, 118(8), 2163–2172. http://doi.org/10.1002/cncr.26494 17- Golla, H., Ale Ahmad, M., Galushko, M., Hampl, J., Maarouf, M., Schroeter, M., et al. (2014). Glioblastoma multiforme from diagnosis to death: a prospective, hospital-based, cohort, pilot feasibility study of patient reported symptoms and needs. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 1–12. http://doi.org/10.1007/s00520-014-2384-z 18- Pierallini, A., Bonamini, M., Pantano, P., Palmeggiani, F., Raguso, M., Osti, M. F., et al. (1998). Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology, 40(3), 150–153. 19- Lee, E. J., Ahn, K. J., Lee, E. K., Lee, Y. S., & Kim, D. B. (2013). Potential role of advanced MRI techniques for the peritumoural region in differentiating glioblastoma multiforme and solitary metastatic lesions. Clinical Radiology, 68(12), e689–97. http://doi.org/10.1016/j.crad.2013.06.021 20- Escalante Abril, P. A., Salazar, M. F., López García, N. L., Madrazo Moya, M. N., Zamora Guerra, Y. U., Mata Mendoza, Y. G., et al. (2015). WHO Grade IV Gliofibroma: A Grading Label Denoting Malignancy for an Otherwise Commonly Misinterpreted Neoplasm. Journal of Pathology and Translational Medicine. http://doi.org/10.4132/jptm.2015.05.20 21- Bükte, Y., Paksoy, Y., Genc, E., & Uca, A. U. (2005). Role of diffusion-weighted MR in differential diagnosis of intracranial cystic lesions. Clinical Radiology, 60(3), 375–383. http://doi.org/10.1016/j.crad.2004.05.019 22- Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987–996. http://doi.org/10.1056/NEJMoa043330 23- Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., et al. (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery, 95(2), 190–198. http://doi.org/10.3171/jns.2001.95.2.0190 24- Jensen, R. L., Mumert, M. L., Gillespie, D. L., Kinney, A. Y., Schabel, M. C., & Salzman, K. L. (2013). Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro-Oncology, not148. http://doi.org/10.1093/neuonc/not148 25- Lemée, J.-M., Clavreul, A., & Menei, P. (2015). Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. Neuro-Oncology, 17(10), 1322–1332. http://doi.org/10.1093/neuonc/nov119 26- Kelly, P. J., Daumas-Duport, C., Kispert, D. B., Kall, B. A., Scheithauer, B. W., & Illig, J. J. (1987). Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. Journal of Neurosurgery, 66(6), 865–874. http://doi.org/10.3171/jns.1987.66.6.0865 27- Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J. Mol. Medicine 77: 527–543, 1999 28- Neufeld G, Cohen T, Gengrinovitch S, Poltrak Z: Vascular endothelial growth factor and its receptors. FASEB J 13: 9–22, 1999 29- Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853–865, 2001 30- Forstreuter F, Lucius R, Mentlein R: Vascular endothelial growth factor (VEGF) induces chemotaxis and proliferation of microglial cells. J Neuroimmunol 132: 93–98, 2002 31- Mentlein R, Held-Feindt J: Angiogenesis factors in gliomas– a new key to tumour therapy? Naturwissenschaften 90: 385–394, 2003 32- Mentlein, R., Forstreuter, F., Mehdorn, H. M., & Held-Feindt, J. (2004). Functional significance of vascular endothelial growth factor receptor expression on human glioma cells. Journal of Neuro-Oncology, 67(1-2), 9–18. 33- Chaloob, M. K., Ali, H. H., Qasim, B. J., & Mohammed, A. S. (2012). Immunohistochemical Expression of Ki-67, PCNA and CD34 in Astrocytomas: A Clinicopathological Study. Oman Medical Journal, 27(5), 368–374. http://doi.org/10.5001/omj.2012.93 34- Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253: 49-53 35- Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FC, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene oc- cur in diverse tumor types. Nature 1989, 342:705-708 36- Haapasalo, H., Isola, J., Sallinen, P., Kalimo, H., Helin, H., & Rantala, I. (1993). Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. The American Journal of Pathology, 142(5), 1347–1351. 37- Habberstad AH, Gulati S, Torp SH. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIa in human anaplastic astrocytomas–an immunohistochemical study. Diagn Pathol 2011;6:43. 38- Gözü H, Bilgiç B, Hazneci J, Sargin H, Erkal F, Sargin M, et al. Is Ki-67 index a useful labeling marker for invasion of pituitary adenomas? Turkish Journal of Endocrinology and Metabolism 2005;4:107-113. 39- Johannessen AL, Torp SH. e clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 2006;12(3):143-147. 40- Isolan GR, Ribas Filho JM, Isolan PM, Giovanini A, Malafaia O, Dini LI, et al. Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins. Arq Neuropsiquiatr 2005 Dec;63(4):997-1004.